ALFA USA News
Straight from the SEC filing
Every SEC filing by Profound Medical Corp. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (14 Oct 2026). Not a valuation or a recommendation.
Up 20.7% over the last month ($5.81 on 14 Sep → $7.01 on 13 Oct). Daily closing prices. Source: Yahoo Finance.
| 14 Sep | $5.81 |
|---|---|
| 15 Sep | $5.68 |
| 16 Sep | $5.83 |
| 17 Sep | $5.89 |
| 18 Sep | $5.86 |
| 21 Sep | $6.10 |
| 22 Sep | $5.89 |
| 23 Sep | $5.74 |
| 24 Sep | $5.60 |
| 25 Sep | $5.76 |
| 28 Sep | $5.92 |
| 29 Sep | $5.72 |
| 30 Sep | $5.80 |
| 1 Oct | $5.85 |
| 2 Oct | $5.84 |
| 5 Oct | $6.03 |
| 6 Oct | $6.08 |
| 7 Oct | $5.68 |
| 8 Oct | $6.91 |
| 9 Oct | $6.90 |
| 12 Oct | $7.25 |
| 13 Oct | $7.01 |
Profound Medical (PROF) shares clinical data showing TULSA-PRO's superior erectile function preservation versus robotic surgery and 0.55T MRI compatibility.
Profound Medical Corp. (PROF) partners with Telix Pharmaceuticals to advance PSMA-informed prostate care, targeting a $70M pipeline and $10M in Q3 revenues.
Track Profound Medical Corp. live
Get the next Profound Medical Corp. SEC filing seconds after it lands.
